PML

  Tysabri-PML Link Drag Biogen Stock. Tysabri troubles could continue to cause a drag on Biogen Idec stock, according to a Wall Street Journal report.  A recently released research note  [...]

  Tysabri Safety Info. The Food & Drug Administration (FDA) is updating Tysabri safety information to include cases of progressive multifocal leukoencephalopathy or PML, a rare brain infection that some [...]

  Tysabri Patients Brain Infection Reported. Two more Tysabri patients have developed progressive multifocal leukoencephalopathy or PML. Both new cases occurred in European patients, according to a Wall Street Journal [...]

Tysabri Patient Stricken with PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy or PML. This brings the total number of cases of the brain infection linked to Tysabri since [...]

Regulators Are Taking a Look At The Link Between Rituxan And PML. U.S. health regulators are taking a look at the lymphoma drug Rituxan because of its possible association with progressive [...]

  Patients Taking Rituxan May Be At Risk. Patients taking Rituxan may be at risk of developing a serious, and often fatal brain infection called progressive multifocal leukoencephalitis (PML), according to [...]

Raptiva Pulled from U.S. Market. Raptiva, an injectable drug used to treat moderate to severe plaque psoriasis, is being withdrawn from the U.S. market. According to Genentech, Raptiva has been [...]

Tysabri Linked to PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy (PML), an often fatal brain disease.  Just three months ago, Biogen Idec said two additional patients had contracted [...]

Part of a class of drugs called immunosuppressants and was approved in 1995. The maker of CellCept,Swiss Drug Maker Roche, has informed healthcare providers that it has modified the “Warnings” and [...]

FDA is Warning Healthcare Professionals Regarding the Risk for PML Patients Receiving Rituxan. The US Food and Drug Administration (FDA) is warning healthcare professionals regarding the risk for progressive multifocal leukoencephalopathy [...]